Budget Impact Analysis of the use of emicizumab for bleeding prophylaxis in patients with Hemophilia A with inhibitors in the Brazilian Health System

• Κύριοι συγγραφείς: Nicolas Segre (Συγγραφέας), Verónica Elizabeth Malta (Συγγραφέας), Tamiê de Camargo Martins (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Instituto Nacional de Assistência Farmacêutica e Farmacoeconomia, 2022-12-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Hemophilia A is a hereditary hemorrhagic disorder characterized by deficiency or dysfunction of the coagulation protein factor VIII. The standard therapy consists of factor VIII replacement, which can lead to the development of neutralizing antibodies (inhibitors), a major complication that implies...